SILO · Silo Pharma, Inc. · Executive Compensation
$1.49
+0.03 (+2.19%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 13, 2026
The latest filing states the doubt was alleviated.
“The positive working capital and the July 2026 Private Placement (see Note 9) serve to mitigate the conditions that historically raised substantial doubt about the Company’s ability to continue as a going concern. The Company believes that it has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months from the date of this filing.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.78M
Shares
1.59M
Volume · Oct 5
212.18K
Avg daily vol (3M)
208.53K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | Chief Executive Officer | $521,750 |
| Daniel Ryweck | Chief Financial Officer | $101,494 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | Chief Executive Officer | $630,051 |
| Daniel Ryweck | Chief Financial Officer | $88,600 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | Chief Executive Officer | $569,009 |
| Daniel Ryweck | Chief Financial Officer | $62,692 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | Chief Executive Officer | $332,250 |
| Daniel Ryweck | Chief Financial Officer (since September 28, 2022) | $15,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Daniel Ryweck | Chief Financial Officer | Appointed | 2022-09-30 |
| Eric Weisblum | Chief Financial Officer | Resigned | 2022-09-30 |
| Daniel Ryweck | Chief Financial Officer | Appointed | 2022-09-30 |
| Jeff Pavell | member of the Board | Appointed | 2022-09-30 |